{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:37:40Z","timestamp":1792291060695,"version":"4.4.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0198363","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T13:36:25Z","timestamp":1532007385000},"page":"e0198363","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":61,"title":["Patterns and predictors of off-label prescription of psychiatric drugs"],"prefix":"10.1371","volume":"13","author":[{"given":"Aishwarya","family":"Vijay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,7,19]]},"reference":[{"key":"ref1","unstructured":"Adams C, Young A. Risky Rx: A Knight Ridder Investigation. Newspaper article series, Nov 2\u20134, 2003. 2008."},{"issue":"14","key":"ref2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJMp0802107","article-title":"Regulating off-label drug use\u2014rethinking the role of the FDA","volume":"358","author":"RS Stafford","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/DHPS.S21079","article-title":"Prevalence and factors associated with off-label antidepressant prescriptions for insomnia","volume":"3","author":"LL Lai","year":"2011","journal-title":"Drug Healthc Patient Saf"},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians","volume":"166","author":"DC Radley","year":"2006","journal-title":"Archives of internal medicine"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archinternmed.2012.340","article-title":"Drug, patient, and physician characteristics associated with off-label prescribing in primary care","volume":"172","author":"T Eguale","year":"2012","journal-title":"Archives of Internal Medicine"},{"issue":"13","key":"ref6","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2165\/00002018-200427130-00006","article-title":"The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients","volume":"27","author":"A Neubert","year":"2004","journal-title":"Drug safety"},{"issue":"9","key":"ref7","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1651-2227.1999.tb00191.x","article-title":"Adverse drug reactions to unlicensed and off\u2010label drugs on paediatric wards: a prospective study","volume":"88","author":"S Turner","year":"1999","journal-title":"Acta Paediatrica"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2125.2002.t01-3-01689.x","article-title":"Adverse drug reactions and off-label drug use in paediatric outpatients","volume":"54","author":"B Horen","year":"2002","journal-title":"British journal of clinical pharmacology"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamainternmed.2015.6058","article-title":"Association of off-label drug use and adverse drug events in an adult population","volume":"176","author":"T Eguale","year":"2016","journal-title":"JAMA internal medicine"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pds.2082","article-title":"Increasing off\u2010label use of antipsychotic medications in the United States, 1995\u20132008","volume":"20","author":"GC Alexander","year":"2011","journal-title":"Pharmacoepidemiology and drug safety"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1176\/ps.2010.61.2.130","article-title":"Off-label use of second-generation antipsychotic agents among elderly nursing home residents","volume":"61","author":"P Kamble","year":"2010","journal-title":"Psychiatric Services"},{"issue":"3","key":"ref12","first-page":"e109","article-title":"Off-label use of antipsychotic medications in Medicaid","volume":"18","author":"DL Leslie","year":"2012","journal-title":"The American journal of managed care"},{"issue":"9","key":"ref13","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1176\/ps.2009.60.9.1175","article-title":"Off-label use of antipsychotic medications in the department of Veterans Affairs health care system","volume":"60","author":"DL Leslie","year":"2009","journal-title":"Psychiatric Services"},{"key":"ref14","unstructured":"Anxiety Disorders Association America. Anxiety Disorder Medications. In: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/adaa.org\/sites\/default\/files\/Medications-Chart_updated-1209.pdf\" xlink:type=\"simple\">https:\/\/adaa.org\/sites\/default\/files\/Medications-Chart_updated-1209.pdf<\/ext-link>, editor. 2009."},{"key":"ref15","unstructured":"Lexapro (escitalopram oxalate) [Internet]. 2009."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"j603","DOI":"10.1136\/bmj.j603","article-title":"Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system","volume":"356","author":"J Wong","year":"2017","journal-title":"bmj"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"752","DOI":"10.4088\/JCP.v65n0605","article-title":"The use of trazodone as a hypnotic: a critical review","volume":"65","author":"SP James","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"17","key":"ref18","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.2165\/0003495-200868170-00001","article-title":"Antidepressants for the treatment of insomnia","volume":"68","author":"MH Wiegand","year":"2008","journal-title":"Drugs"},{"key":"ref19","article-title":"Trazodone for Insomnia: A Systematic Review","volume":"14","author":"KY Jaffer","year":"2017","journal-title":"Innovations in Clinical Neuroscience"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1592\/phco.28.12.1443","article-title":"Prioritizing Future Research on Off\u2010Label Prescribing: Results of a Quantitative Evaluation","volume":"28","author":"SM Walton","year":"2008","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3821\/145.6.cpj280","article-title":"Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists","volume":"145","author":"C Fukada","year":"2012","journal-title":"Canadian Pharmacists Journal\/Revue des Pharmaciens du Canada"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Schappert SM, Rechsteiner EA. Ambulatory medical care utilization estimates for 2006. 2008.","DOI":"10.1037\/e587152010-001"},{"key":"ref23","unstructured":"FDA. Pediatric Expertise for Advisory Panels; Guidance for Industry and FDA Staff 2015. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.fda.gov\/RegulatoryInformation\/Guidances\/ucm082185.htm\" xlink:type=\"simple\">https:\/\/www.fda.gov\/RegulatoryInformation\/Guidances\/ucm082185.htm<\/ext-link>."},{"key":"ref24","unstructured":"CMS. Anticonvulsant Medications: U.S. Food and Drug Administration-Approved Indications and Most Common Dosages for Use in Adults. 2013."},{"key":"ref25","unstructured":"Lexicon Plus [Internet]. 2013. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www2.cdc.gov\/drugs\/applicationnav1.asp\" xlink:type=\"simple\">https:\/\/www2.cdc.gov\/drugs\/applicationnav1.asp<\/ext-link>."},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"972","DOI":"10.4088\/JCP.v67n0615","article-title":"Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001","volume":"67","author":"H Chen","year":"2006","journal-title":"The Journal of clinical psychiatry"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.2041-210X.2009.00001.x","article-title":"A protocol for data exploration to avoid common statistical problems","volume":"1","author":"AF Zuur","year":"2010","journal-title":"Methods Ecol Evol"},{"key":"ref28","author":"DW Hosmer Jr","year":"2013"},{"key":"ref29","unstructured":"NCHS. NAMCS and NHAMCS. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.cdc.gov\/nchs\/ahcd\/ahcd_questionnaires.htm2017\" xlink:type=\"simple\">https:\/\/www.cdc.gov\/nchs\/ahcd\/ahcd_questionnaires.htm2017<\/ext-link>."},{"key":"ref30","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. 2016."},{"issue":"5","key":"ref31","article-title":"Review of evidence for use of antidepressants in bipolar depression","volume":"16","author":"SJ McInerney","year":"2014","journal-title":"The primary care companion for CNS disorders"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpsyc.1993.01820230054005","article-title":"Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam","volume":"50","author":"K Rickels","year":"1993","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/03007995.2017.1294055","article-title":"The use of adjunctive antipsychotics to treat depression in UK primary care","volume":"33","author":"F Lamy","year":"2017","journal-title":"Current Medical Research and Opinion"},{"key":"ref34","unstructured":"Abilify (aripiprazole) Labels [Internet]. 2016."},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"2-","DOI":"10.1192\/apt.23.1.2","article-title":"Pharmacological treatment for psychotic depression","volume":"23","author":"J Wijkstra","year":"2017","journal-title":"BJPsych Advances"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Patwardhan AR. Physicians-Pharmaceutical Sales Representatives Interactions and Conflict of Interest. 2016.","DOI":"10.1177\/0046958016667597"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"e1001561","DOI":"10.1371\/journal.pmed.1001561","article-title":"Interactions between non-physician clinicians and industry: a systematic review","volume":"10","author":"Q Grundy","year":"2013","journal-title":"PLoS medicine"},{"key":"ref38","article-title":"PharmaVoice","author":"E Pena","year":"2003"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jamainternmed.2015.8155","article-title":"Free speech and pharmaceutical regulation\u2014fishy business","volume":"176","author":"A Kapczynski","year":"2016","journal-title":"JAMA internal medicine"},{"key":"ref40","unstructured":"Canada H. Good Pharmacovigilance Practices (GVP) Guidelines. 2013."},{"issue":"8","key":"ref41","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jama.2017.21897","article-title":"Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts","volume":"319","author":"JD Wallach","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.socscimed.2011.11.046","article-title":"Pharmacovigilance in Europe and North America: divergent approaches","volume":"75","author":"M Wiktorowicz","year":"2012","journal-title":"Social Science & Medicine"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1176\/appi.ajp.163.1.5","article-title":"Beyond efficacy: the STAR* D trial","volume":"163","author":"TR Insel","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5694\/j.1326-5377.2006.tb00689.x","article-title":"Off-label use of medicines: consensus recommendations for evaluating appropriateness","volume":"185","author":"M Gazarian","year":"2006","journal-title":"Medical Journal of Australia"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"i4189","DOI":"10.1136\/bmj.i4189","article-title":"Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study","volume":"354","author":"W Fleischman","year":"2016","journal-title":"bmj"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"f264","DOI":"10.1136\/bmj.f264","article-title":"Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis","volume":"346","author":"M King","year":"2013","journal-title":"Bmj"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0198363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T21:19:00Z","timestamp":1571606340000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0198363"}},"subtitle":[],"editor":[{"given":"Andrea","family":"Romigi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0198363","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,19]]}}}